
The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

Your AI-Trained Oncology Knowledge Connection!


The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

BGB-16673-101 (NCT05006716) is a phase 1 study of a bruton tyrosine kinase degrader (BGB-16673) in patients with relapsed or refractory CLL/SLL.

Ricardo D. Parrondo, MD, discusses the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

Ricardo D. Parrondo, MD, discusses the phase 1b/2 RedirecTT-1 of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Ricardo D. Parrondo, MD, discusses the exploration of the non-BCMA CAR T-cell target GPRC5D in multiple myeloma.

Ricardo D. Parrondo, MD, discusses the current treatment landscape of mantle cell lymphoma and highlights ongoing areas of investigation in other hematologic malignancies.

Ricardo D. Parrondo, MD, discusses the clinical benefit seen with momelotinib in anemic myelofibrosis, and where it fits into the current treatment paradigm in this disease landscape.

Published: October 6th 2023 | Updated:

Published: September 5th 2024 | Updated: